Equipped in New Products for the Second Half of the Year
Samsung Electronics announced that the 'Irregular Heart Rhythm Notification (IHRN)' feature of the 'Samsung Health Monitor' app recently received approval from the Korean Ministry of Food and Drug Safety (MFDS), following its approval by the U.S. FDA in May.
The 'Irregular Heart Rhythm Notification' feature is scheduled to be installed in the new Galaxy Watch model launching in the second half of the year and will initially be supported in 13 global markets, including Korea and the United States. Subsequently, it will be expanded to the 'Galaxy Watch5 and Watch4 series' through a software update.
The 'Irregular Heart Rhythm Notification' feature uses the Galaxy Watch's 'BioActive Sensor' to detect continuous irregular heartbeats in users, identifying them as abnormal signs and providing alert messages about the possibility of 'atrial fibrillation.' Along with the currently supported blood pressure measurement, electrocardiogram (ECG) measurement, and heart rate measurement functions on the Galaxy Watch, it aims to offer users more meaningful information about cardiovascular health.
Meanwhile, Samsung Electronics provides health management services that allow users in 74 markets to measure blood pressure and electrocardiograms through the 'Samsung Health Monitor' app.
Hon Pak, Executive Vice President and Head of the Digital Health Team at Samsung Electronics MX Business Division, said, "Samsung Electronics is committed to enabling users to obtain information about their heart health by providing monitoring tools such as blood pressure measurement and irregular heart rhythm notifications," adding, "We will continue our efforts to provide health solutions that can protect our customers' health."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
